Immunogenicity and Reactogenicity of SARS-CoV-2 Vaccines in Patients With Cancer: The CANVAX Cohort Study.
Journal
Journal of clinical oncology : official journal of the American Society of Clinical Oncology
ISSN: 1527-7755
Titre abrégé: J Clin Oncol
Pays: United States
ID NLM: 8309333
Informations de publication
Date de publication:
01 01 2022
01 01 2022
Historique:
pubmed:
10
11
2021
medline:
5
1
2022
entrez:
9
11
2021
Statut:
ppublish
Résumé
The immunogenicity and reactogenicity of SARS-CoV-2 vaccines in patients with cancer are poorly understood. We performed a prospective cohort study of adults with solid-organ or hematologic cancers to evaluate anti-SARS-CoV-2 immunoglobulin A/M/G spike antibodies, neutralization, and reactogenicity ≥ 7 days following two doses of mRNA-1273, BNT162b2, or one dose of Ad26.COV2.S. We analyzed responses by multivariate regression and included data from 1,638 healthy controls, previously reported, for comparison. Between April and July 2021, we enrolled 1,001 patients; 762 were eligible for analysis (656 had neutralization measured). mRNA-1273 was the most immunogenic (log Immune responses to SARS-CoV-2 vaccines are modestly impaired in patients with cancer. These data suggest utility of antibody testing to identify patients for whom additional vaccine doses may be effective and appropriate, although larger prospective studies are needed.
Identifiants
pubmed: 34752147
doi: 10.1200/JCO.21.01891
pmc: PMC8683230
doi:
Substances chimiques
COVID-19 Vaccines
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
12-23Subventions
Organisme : NIDA NIH HHS
ID : DP2 DA040254
Pays : United States
Références
Cell. 2021 Jan 21;184(2):476-488.e11
pubmed: 33412089
Blood. 2021 Jul 1;137(26):3674-3676
pubmed: 33861315
JAMA Oncol. 2021 Aug 1;7(8):1133-1140
pubmed: 34047765
Nature. 2021 Feb;590(7847):630-634
pubmed: 33276369
N Engl J Med. 2021 Feb 4;384(5):403-416
pubmed: 33378609
Science. 2021 Sep 17;373(6561):eabj0299
pubmed: 34529476
N Engl J Med. 2021 Apr 8;384(14):1372-1374
pubmed: 33691060
J Infect Dis. 2022 Apr 1;225(7):1141-1150
pubmed: 34888672
Ann Intern Med. 2021 Sep;174(9):1330-1332
pubmed: 34125572
N Engl J Med. 2020 Dec 31;383(27):2603-2615
pubmed: 33301246
Cell. 2021 Apr 29;184(9):2372-2383.e9
pubmed: 33743213
Cancer Cell. 2021 Aug 9;39(8):1091-1098.e2
pubmed: 34214473
N Engl J Med. 2021 Jun 10;384(23):2187-2201
pubmed: 33882225
JAMA Oncol. 2021 Oct 1;7(10):1507-1513
pubmed: 34236381
JAMA. 2021 Jun 1;325(21):2201-2202
pubmed: 33818592
N Engl J Med. 2021 Aug 12;385(7):661-662
pubmed: 34161700
Lancet. 2020 Jun 20;395(10241):1907-1918
pubmed: 32473681
Open Forum Infect Dis. 2021 Jun 30;8(7):ofab353
pubmed: 34337100
Ann Oncol. 2021 Aug;32(8):1053-1055
pubmed: 33932508
Science. 2020 Aug 21;369(6506):956-963
pubmed: 32540903
Cancer Cell. 2020 Nov 9;38(5):629-646
pubmed: 33049215
Nat Med. 2021 Jul;27(7):1205-1211
pubmed: 34002089
Lancet Oncol. 2021 Jun;22(6):765-778
pubmed: 33930323
Vaccine. 2021 Jul 22;39(32):4423-4428
pubmed: 34210573
Lancet Haematol. 2021 Jun;8(6):e389-e392
pubmed: 33887255
Cancer Cell. 2021 Aug 9;39(8):1081-1090.e2
pubmed: 34133951
JAMA. 2021 Jul 6;326(1):46-55
pubmed: 34081073